Citius Pharmaceuticals, Inc. (CTXR) is a biotherapeutics company engaged in developing therapies for cancer care. Its shares dropped minutely by 1.60% to be $1.84 during Tuesday’s regular trading. Its price swelled as of the writing in the premarket session of Wednesday by 19.02%. The one-year price range of its shares on the lower side is $1.31, while the higher side is $4.56 with a market cap of $268 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
CTXR stated on April 6, the topline outcomes from its pivotal Phase 3 clinical studies of I/ONTAK (E7777) which is an altered IL-2-diphtheria toxin fusion protein, used in the treatment of persistent or recurrent cutaneous T-cell lymphoma. The topline outcomes remained consistent with the previous formulation. Furthermore, no safety signals were identified in the recent trials. Based on the results, the company expects to file a biologics license application with FDA in the H2 2022.
The pharmaceutical businesses are on a verge of decline in the past year the main reasons being ever-increasing petroleum products prices due to the Russia-Ukraine conflict as Russia is one of the major exporters of crude oil products. The analysts are cautioning the industry against the turmoil and encouraging the initiation of different projects or the completion of projects to the companies to get rid of the decreasing trajectory.
CTXR: Company Outlook
CTXR posted -$0.06 in its EPS, which remained in line with expectations. The company presented at multiple March Investor Conferences highlighting its achievements. It also updated on the acceptance IND application of its Phase 2 trials of Halo-Lido
CTXR stock jumped instantly in Wednesday’s premarket as the company announced optimistic topline results from its I/ONTAK (E7777) trials. The shares dwindled during the last six months by 9% by remained 0.55% up in the past full year. The investors are optimistic that the company’s growth will increase following positive announcements.